معرفی
Karin Lindberg is a Researcher at Karolinska Institutet's Department of Oncology-Pathology, holding a PhD (2015) and medical degree (2005). Her work focuses on precision radiotherapy for lung cancer, particularly stereotactic body radiation therapy (SBRT), with extensive contributions to clinical trials and translational research within Kristina Viktorsson's and Simon Ekman's research groups.
Education
- Doctor of Philosophy, Department of Oncology-Pathology, Karolinska Institutet (2015)
- Medical Degree, Karolinska Institutet (2005)
Dr. Lindberg's research centers on lung cancer radiotherapy optimization, with emphasis on SBRT for early-stage and central tumors. She investigates molecular mechanisms, biomarkers, and clinical outcomes through multi-center trials like HILUS. Her work bridges preclinical, translational, and clinical domains to refine radiation dosing, minimize toxicity, and integrate novel therapies. Key areas include:
- Stereotactic Body Radiation Therapy (SBRT)
- Ultracentral Lung Tumor Management
- Radiation-Immunotherapy Synergy
- Toxicity Risk Prediction
- Emergency Radiation Response
Analysis of her 15 most recent publications (2020-2025) reveals dominant themes in SBRT for central/ultracentral lung tumors, dose constraint validation, and radiotherapy-immunotherapy combinations. She leads pivotal Nordic trials (e.g., HILUS) addressing therapeutic windows and toxicity risks, while contributing to global consensus guidelines during crises like the COVID-19 pandemic.
No scientific awards are documented in the source material.
Dr. Lindberg collaborates with the Precision Cancer Medicine groups of Kristina Viktorsson and Simon Ekman, focusing on molecular mechanisms and clinical translation. Her research infrastructure includes BioClinicum facilities in Solna, leveraging Karolinska Institutet's clinical trial networks for lung cancer radiotherapy innovation.
